Bristol-Celgene Merger Leaps FTC Clearance; Deal Set To Close Wednesday

Bristol-Myers Squibb (BMY) and Celgene (CELG) said late Friday the U.S. Federal Trade Commission cleared their planned merger.

The FTC decision clears the path for Bristol-Myers to wrap its $74 billion Celgene merger on Wednesday, the pharmaceutical company said in a news release. The pharma giant announced its Celgene merger in January.